New device aims to filter toxins in liver crisis

NCT ID NCT06079021

Recruiting now Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the CytoSorb blood-filtering device to standard hospital care can better remove waste products like bilirubin and ammonia in people with sudden worsening of chronic liver disease. Twenty adults with severe liver failure will receive the device for 72 hours, and their outcomes will be compared to a similar group from the past who got standard care alone. The goal is to see if the device can reduce liver toxins and improve brain function during this critical illness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE-ON-CHRONIC LIVER FAILURE ANTICOAGULANT ADVERSE REACTION SARCOPENIA ULTRASONOGRAPHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UZA
RECRUITING

Edegem, Antwerp, 2650, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••